News

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
Early Anthropic hire raises $15M for AIUC to insure AI agents, helping enterprises deploy artificial intelligence securely with risk coverage and safety standards.
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.
GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...
Following a recommendation from a panel of CDC advisors, HHS Secretary Robert F. Kennedy Jr. on Wednesday ordered that the preservative thimerosal be removed from all flu vaccines. In June, the CDC's ...
AstraZeneca and GSK shares were among today’s FTSE 100 index beneficiaries as risk appetite surged on the back of Japan’s US trade deal. London’s top flight added another 0.6% to a fresh record of ...
Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...
The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...
Around 100 UK business representatives attended the London conference, which is part of the 2025 Lin-gang Special Area Global ...